Imagion Biosystems Successfully Completes Toxicology Study

Matthew Wygant Investor Updates, News

Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the successful completion of a toxicology safety study of its lead MagSense™ nanoparticle formulation for the detection of HER2 metastatic breast cancer.

Read the announcement.